Barclays PLC Corcept Therapeutics Inc Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Barclays PLC holds 168,527 shares of CORT stock, worth $9.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

168,527

Previous 325,953 48.3%

Holding current value

$9.34 Million

Previous $15.1 Million 43.7%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$44.66 - $60.85 $7.03 Million - $9.58 Million	-157,426 Reduced 48.3%	168,527 $8.49 Million
Q3 2024 Nov 15, 2024	BUY	$29.51 - $46.26 $1.82 Million - $2.85 Million	61,510 Added 23.26%	325,953 $15.1 Million
Q2 2024 Aug 14, 2024	SELL	$22.21 - $34.48 $239,890 - $372,418	-10,801 Reduced 3.92%	264,443 $8.59 Million
Q1 2024 May 15, 2024	BUY	$21.1 - $27.46 $1.98 Million - $2.57 Million	93,693 Added 51.61%	275,244 $6.93 Million
Q4 2023 Feb 15, 2024	BUY	$24.82 - $32.88 $2.67 Million - $3.54 Million	107,565 Added 145.39%	181,551 $5.9 Million
Q3 2023 Nov 07, 2023	BUY	$21.97 - $33.8 $50,509 - $77,706	2,299 Added 3.21%	73,986 $2.02 Million
Q2 2023 Aug 03, 2023	SELL	$21.44 - $25.15 $306,034 - $358,991	-14,274 Reduced 16.61%	71,687 $1.6 Million
Q1 2023 May 04, 2023	BUY	$19.2 - $24.47 $8,198 - $10,448	427 Added 0.5%	85,961 $1.86 Million
Q4 2022 Feb 13, 2023	BUY	$19.95 - $29.96 $38,204 - $57,373	1,915 Added 2.29%	85,534 $1.74 Million
Q3 2022 Nov 03, 2022	BUY	$24.7 - $29.12 $169,516 - $199,850	6,863 Added 8.94%	83,619 $2.15 Million
Q2 2022 Aug 12, 2022	SELL	$17.33 - $25.3 $618,386 - $902,779	-35,683 Reduced 31.74%	76,756 $1.83 Million
Q1 2022 May 16, 2022	SELL	$16.53 - $25.21 $1 Million - $1.53 Million	-60,638 Reduced 35.04%	112,439 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$17.1 - $23.34 $151,317 - $206,535	8,849 Added 5.39%	173,077 $3.43 Million
Q3 2021 Nov 09, 2021	BUY	$19.68 - $22.53 $1.79 Million - $2.05 Million	91,093 Added 124.55%	164,228 $3.23 Million
Q2 2021 Aug 13, 2021	SELL	$19.97 - $24.43 $2.14 Million - $2.61 Million	-106,929 Reduced 59.38%	73,135 $1.61 Million
Q1 2021 May 13, 2021	SELL	$23.49 - $30.56 $746,794 - $971,563	-31,792 Reduced 15.01%	180,064 $4.28 Million
Q4 2020 Feb 11, 2021	SELL	$16.78 - $27.3 $1.06 Million - $1.73 Million	-63,239 Reduced 22.99%	211,856 $5.54 Million
Q3 2020 Nov 12, 2020	BUY	$12.46 - $19.98 $175,162 - $280,878	14,058 Added 5.39%	275,095 $4.79 Million
Q2 2020 Aug 12, 2020	BUY	$11.0 - $18.26 $257,730 - $427,831	23,430 Added 9.86%	261,037 $4.39 Million
Q1 2020 May 13, 2020	BUY	$10.11 - $14.04 $280,410 - $389,413	27,736 Added 13.22%	237,607 $2.83 Million
Q4 2019 Feb 10, 2020	BUY	$12.06 - $16.96 $1.24 Million - $1.74 Million	102,558 Added 95.57%	209,871 $2.54 Million
Q3 2019 Nov 14, 2019	SELL	$10.41 - $14.66 $69,871 - $98,397	-6,712 Reduced 5.89%	107,313 $1.52 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $12.76 $130,396 - $170,129	13,333 Added 13.24%	114,025 $1.27 Million
Q1 2019 May 15, 2019	BUY	$10.03 - $15.71 $491,159 - $769,302	48,969 Added 94.68%	100,692 $1.18 Million
Q4 2018 Feb 14, 2019	SELL	$11.29 - $17.19 $814,731 - $1.24 Million	-72,164 Reduced 58.25%	51,723 $691,000
Q3 2018 Nov 14, 2018	BUY	$12.27 - $15.65 $1.05 Million - $1.34 Million	85,571 Added 223.33%	123,887 $1.74 Million
Q2 2018 Aug 14, 2018	BUY	$15.3 - $19.69 $148,333 - $190,894	9,695 Added 33.87%	38,316 $602,000
Q1 2018 May 15, 2018	SELL	$14.59 - $25.5 $597,548 - $1.04 Million	-40,956 Reduced 58.86%	28,621 $470,000
Q4 2017 Feb 14, 2018	SELL	$15.77 - $20.72 $266,481 - $350,126	-16,898 Reduced 19.54%	69,577 $1.26 Million
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $1.06 Million - $1.67 Million	86,475	86,475 $1.67 Million

Others Institutions Holding CORT

# of Institutions

403

Shares Held

84.3M

Call Options Held

1.04M

Put Options Held

1.33M

View Full List

About CORCEPT THERAPEUTICS INC

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.93B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

More about CORT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account